Epzicom Related Published Studies
Well-designed clinical trials related to Epzicom (Abacavir / Lamivudine)
Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection. [2006.09]
Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study). [2006.04.15]
Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL). [2005.12.01]
Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. [2005.12.01]
Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients. [2005.07.01]
Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial). [2002.12]
Well-designed clinical trials possibly related to Epzicom (Abacavir / Lamivudine)
Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase. [2007.09]
An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy. [2006]
Other research related to Epzicom (Abacavir / Lamivudine)
CD4 count improvement following tenofovir to abacavir switch in a patient with persistent lymphopenia despite an undetectable viral load. [2008.08]
Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naive patients: a 48-week pilot study. [2008.05]
Short-term Safety and Tolerability of a Once-Daily Fixed-Dose Abacavir-Lamivudine Combination versus Twice-Daily Dosing of Abacavir and Lamivudine as Separate Components: Findings from the ALOHA Study. [2008.03]
Incidence of abacavir hypersensitivity reactions in euroSIDA. [2008]
Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. [2007.10.18]
Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up. [2007.05]
Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naive subjects: a 48-week pilot study. [2006.11]
Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children. [2006.06]
Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen. [2006]
Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection. [2005.12]
Abacavir plus lamivudine: a review of their combined use in the management of HIV infection. [2005]
Other possibly related research studies
[New antiretroviral treatment modalities] [2005.06.04]
Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study. [2006.05]
Hepatitis B in liver transplant recipients. [2006.11]
An update and review of antiretroviral therapy. [2006.08]
Nucleoside analogue reverse transcriptase inhibitor options: a re-examination of the class. [2006.10]
Evolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir. [2006.11]
Triple-nucleoside analog antiretroviral therapy: is there still a role in clinical practice? A review. [2005.06.02]
Nucleoside and nucleotide reverse transcriptase inhibitors in children. [2007]
Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients. [2008.04]
Efficacy and safety of once-daily regimens in the treatment of HIV infection. [2008]
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. [2008.08.06]
Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naive patients with HIV-1 infection. [2008.08]
|
